Quick Answer
Aptevo Therapeutics Inc. reported Stockholders Equity of $17.38 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed an increase of +265.5% in Stockholders Equity from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $63.75 million | Q1 2017: $61.49 million | Q2 2017: $51.42 million | Q3 2017: $90.31 million | Q1 2018: $68.36 million | Q2 2018: $56.03 million | Q3 2018: $44.00 million | Q1 2019: $39.13 million | Q2 2019: $26.20 million | Q3 2019: $19.75 million | Q1 2020: $15.15 million | Q2 2020: $8.65 million | Q3 2020: $2.20 million | Q1 2021: $10.50 million | Q2 2021: $13.88 million | Q3 2021: $7.29 million | Q1 2022: -$5.88 million | Q2 2022: $23.05 million | Q3 2022: $15.76 million | Q1 2023: $23.26 million | Q2 2023: $16.25 million | Q3 2023: $14.72 million | Q1 2024: $6.10 million | Q2 2024: $4.46 million | Q3 2024: $4.42 million | Q1 2025: -$1.47 million | Q2 2025: $6.52 million | Q3 2025: $17.39 million.
- Over the full 14 years of available data (2014 to 2025), Aptevo Therapeutics Inc.'s Stockholders Equity has declined by 81.6%.
- Historical annual values: Fiscal year 2025: $17.38 million | Fiscal year 2024: $4.76 million | Fiscal year 2023: $12.22 million | Fiscal year 2022: $17.97 million | Fiscal year 2021: $1.22 million | Fiscal year 2020: $16.59 million | Fiscal year 2019: $11.84 million | Fiscal year 2018: $30.41 million | Fiscal year 2017: $82.04 million | Fiscal year 2016: $50.57 million | Fiscal year 2016: $97.20 million | Fiscal year 2016: $89.86 million | Fiscal year 2015: $88.62 million | Fiscal year 2014: $94.61 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: